PMID- 28112381
OWN - NLM
STAT- MEDLINE
DCOM- 20170315
LR  - 20220408
IS  - 1791-244X (Electronic)
IS  - 1107-3756 (Print)
IS  - 1107-3756 (Linking)
VI  - 39
IP  - 3
DP  - 2017 Mar
TI  - Notoginsenoside R1 attenuates glucose-induced podocyte injury via the inhibition 
      of apoptosis and the activation of autophagy through the PI3K/Akt/mTOR signaling 
      pathway.
PG  - 559-568
LID - 10.3892/ijmm.2017.2864 [doi]
AB  - Injury to terminally differentiated podocytes contributes ignificantly to 
      proteinuria and glomerulosclerosis. The aim of this study was to examine the 
      protective effects of notoginsenoside R1 (NR1) on the maintenance of podocyte 
      number and foot process architecture via the inhibition of apoptosis, the 
      induction of autophagy and the maintenance pf podocyte biology in target cells. 
      The effects of NR1 on conditionally immortalized human podocytes under high 
      glucose conditions were evaluated by determining the percentage apoptosis, the 
      percentage autophagy and the expression levels of slit diaphragm proteins. Our 
      results revealed that NR1 protected the podocytes against high glucose-induced 
      injury by decreasing apoptosis, increasing autophagy and by promoting 
      cytoskeletal recovery. The phosphoinositide 3-kinase (PI3K)/Akt/mammalian target 
      of rapamycin (mTOR) signaling pathway was further investigated in order to 
      elucidate the mechanisms responsible for the protective effects of NR1 on 
      podocytes. Our data indicated that treatment with NR increased the 
      phosphorylation levels of PI3K, Akt and mTOR, leading to the activation of the 
      PI3K/Akt/mTOR signaling pathway in podocytes. To the best of our knowledge, this 
      is the first in vitro study to demonstrate that NR1 protects podocytes by 
      activating the PI3K/Akt/mTOR pathway.
FAU - Huang, Guodong
AU  - Huang G
AD  - Department of Nephrology, Ruikang Hospital Affiliated to Guangxi University of 
      Chinese Medicine, Nanning, Guangxi 530011, P.R. China.
FAU - Zou, Bingyu
AU  - Zou B
AD  - Department of Gynecology, Sichuan Academy of Medical Science and Sichuan 
      Provincial People's Hospital, Chengdu, Sichuan 610072, P.R. China.
FAU - Lv, Jianzhen
AU  - Lv J
AD  - School of Basic Medical Science, Guangxi University of Chinese Medicine, Nanning, 
      Guangxi 530001, P.R. China.
FAU - Li, Tongyu
AU  - Li T
AD  - School of Basic Medical Science, Guangxi University of Chinese Medicine, Nanning, 
      Guangxi 530001, P.R. China.
FAU - Huai, Guoli
AU  - Huai G
AD  - Department of Biomedical Engineering, Medical School of University of Electronic 
      Science and Technology of China, Chengdu, Sichuan 610054, P.R. China.
FAU - Xiang, Shaowei
AU  - Xiang S
AD  - Department of Nephrology, Ruikang Hospital Affiliated to Guangxi University of 
      Chinese Medicine, Nanning, Guangxi 530011, P.R. China.
FAU - Lu, Shilong
AU  - Lu S
AD  - School of Basic Medical Science, Guangxi University of Chinese Medicine, Nanning, 
      Guangxi 530001, P.R. China.
FAU - Luo, Huan
AU  - Luo H
AD  - Department of Nephrology, Ruikang Hospital Affiliated to Guangxi University of 
      Chinese Medicine, Nanning, Guangxi 530011, P.R. China.
FAU - Zhang, Yaping
AU  - Zhang Y
AD  - Department of Nephrology, Ruikang Hospital Affiliated to Guangxi University of 
      Chinese Medicine, Nanning, Guangxi 530011, P.R. China.
FAU - Jin, Yi
AU  - Jin Y
AD  - Center for Perinatal Research, Research Institute at Nationwide Children's 
      Hospital, Columbus, OH 43215, USA.
FAU - Wang, Yi
AU  - Wang Y
AD  - Department of Biomedical Engineering, Medical School of University of Electronic 
      Science and Technology of China, Chengdu, Sichuan 610054, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20170120
PL  - Greece
TA  - Int J Mol Med
JT  - International journal of molecular medicine
JID - 9810955
RN  - 0 (Biomarkers)
RN  - 0 (Ginsenosides)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - IY9XDZ35W2 (Glucose)
RN  - Z62692362Z (notoginsenoside R1)
SB  - IM
MH  - Apoptosis/*drug effects
MH  - Biomarkers
MH  - Cell Line
MH  - Gene Expression
MH  - Ginsenosides/*pharmacology
MH  - Glucose/*metabolism/pharmacology
MH  - Humans
MH  - Phosphatidylinositol 3-Kinases/*metabolism
MH  - Podocytes/*drug effects/*metabolism
MH  - Proto-Oncogene Proteins c-akt/*metabolism
MH  - *Signal Transduction
MH  - TOR Serine-Threonine Kinases/*metabolism
PMC - PMC5360354
EDAT- 2017/01/24 06:00
MHDA- 2017/03/16 06:00
PMCR- 2017/01/20
CRDT- 2017/01/24 06:00
PHST- 2015/09/06 00:00 [received]
PHST- 2017/01/11 00:00 [accepted]
PHST- 2017/01/24 06:00 [pubmed]
PHST- 2017/03/16 06:00 [medline]
PHST- 2017/01/24 06:00 [entrez]
PHST- 2017/01/20 00:00 [pmc-release]
AID - ijmm-39-03-0559 [pii]
AID - 10.3892/ijmm.2017.2864 [doi]
PST - ppublish
SO  - Int J Mol Med. 2017 Mar;39(3):559-568. doi: 10.3892/ijmm.2017.2864. Epub 2017 Jan 
      20.